DESTINY-Breast06

NCT04494425 📎

Regimen

Experimental
Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks.
Control
Treatment of physician's choice chemotherapy.

Population

HR-positive, HER2-low or HER2-ultralow (IHC 0 with membrane staining) metastatic breast cancer that progressed on >=2 lines of endocrine-based therapy, chemotherapy-naive in the metastatic setting.

Key finding

DESTINY-Breast06 further extended T-DXd's reach to HER2-ultralow (IHC 0 with staining) MBC after endocrine therapy. FDA approved Jan 2025 for HR+/HER2-low and ultralow post-endocrine. Reshapes chemo-naive MBC sequencing.

Source: PMID 39282896

Timeline

  • Publication: 2024 Dec 5

Guideline citations

  • NCCN BREAST